In brief: Blue Water Vaccines licensing flu vaccine from Oxford Uni

First-in-human trial of universal flu vaccine candidate begins
Credit: Lemau Studio

Blue Water Vaccines is raising $15 million to exclusively license a novel a potentially revolutionary universal flu vaccine via an option agreement with the UK’s University of Oxford.

Developed by scientists at Oxford University, the vaccine protects against all influenza strains by targeting parts of the virus that induce a protective immune response but are also limited in variability.

The technology has the potential of providing life-long immunity against flu.

Terms of the agreement were not disclosed.